ID   MET-1
AC   CVCL_LN09
SY   MET1; SCCT
DR   cancercelllines; CVCL_LN09
DR   CancerTools; 153539
DR   Cosmic; 2688659
DR   GEO; GSM2611467
DR   GEO; GSM2611468
DR   GEO; GSM2611469
DR   Wikidata; Q54905316
DR   Ximbio; 153539
RX   PubMed=10772384;
RX   PubMed=11121147;
RX   PubMed=24662767;
RX   PubMed=29755650;
RX   PubMed=30202019;
RX   PubMed=31336867;
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Met (c.646G>A); ClinVar=VCV000182965; Zygosity=Unspecified (PubMed=24662767).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Hand, skin; UBERON=UBERON_0001519.
CC   Cell type: Keratinocyte; CL=CL_0000312.
ST   Source(s): PubMed=31336867
ST   Amelogenin: X,Y
ST   CSF1PO: 13
ST   D13S317: 8,12
ST   D16S539: 11,13
ST   D18S51: 18,19
ST   D19S433: 14
ST   D21S11: 30.2,33.2
ST   D2S1338: 17,21
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 7,8
ST   D8S1179: 12,15
ST   FGA: 24
ST   TH01: 9.3
ST   TPOX: 9,11
ST   vWA: 18,19
DI   NCIt; C4819; Skin squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_LN10 ! MET-2
OI   CVCL_LN11 ! MET-3
OI   CVCL_LN12 ! MET-4
OI   CVCL_LN13 ! PM-1 [Human oral dysplasia]
OI   CVCL_VJ50 ! SCCT9
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 30-01-24; Version: 11
//
RX   PubMed=10772384; DOI=10.1034/j.1600-0625.2000.009002104.x;
RA   Proby C.M., Purdie K.J., Sexton C.J., Purkis P., Navsaria H.A.,
RA   Stables J.N., Leigh I.M.;
RT   "Spontaneous keratinocyte cell lines representing early and advanced
RT   stages of malignant transformation of the epidermis.";
RL   Exp. Dermatol. 9:104-117(2000).
//
RX   PubMed=11121147; DOI=10.1046/j.1523-1747.2000.00173.x;
RA   Popp S., Waltering S., Holtgreve-Grez H., Jauch A., Proby C.M.,
RA   Leigh I.M., Boukamp P.;
RT   "Genetic characterization of a human skin carcinoma progression model:
RT   from primary tumor to metastasis.";
RL   J. Invest. Dermatol. 115:1095-1103(2000).
//
RX   PubMed=24662767; DOI=10.1038/jid.2014.154; PMCID=PMC4753672;
RA   South A.P., Purdie K.J., Watt S.A., Haldenby S., den Breems N.Y.,
RA   Dimon M., Arron S.T., Kluk M.J., Aster J.C., McHugh A., Xue D.J.,
RA   Dayal J.H.S., Robinson K.S., Rizvi S.M.H., Proby C.M., Harwood C.A.,
RA   Leigh I.M.;
RT   "NOTCH1 mutations occur early during cutaneous squamous cell
RT   carcinogenesis.";
RL   J. Invest. Dermatol. 134:2630-2638(2014).
//
RX   PubMed=29755650; DOI=10.18632/oncotarget.24750; PMCID=PMC5945540;
RA   McHugh A., Fernandes K., South A.P., Mellerio J.E., Salas-Alanis J.C.,
RA   Proby C.M., Leigh I.M., Saville M.K.;
RT   "Preclinical comparison of proteasome and ubiquitin E1 enzyme
RT   inhibitors in cutaneous squamous cell carcinoma: the identification of
RT   mechanisms of differential sensitivity.";
RL   Oncotarget 9:20265-20281(2018).
//
RX   PubMed=30202019; DOI=10.1038/s41467-018-06027-1; PMCID=PMC6131170;
RA   Inman G.J., Wang J., Nagano A., Alexandrov L.B., Purdie K.J.,
RA   Taylor R.G., Sherwood V., Thomson J., Hogan S., Spender L.C.,
RA   South A.P., Stratton M.R., Chelala C., Harwood C.A., Proby C.M.,
RA   Leigh I.M.;
RT   "The genomic landscape of cutaneous SCC reveals drivers and a novel
RT   azathioprine associated mutational signature.";
RL   Nat. Commun. 9:3667.1-3667.14(2018).
//
RX   PubMed=31336867; DOI=10.3390/ijms20143428; PMCID=PMC6678499;
RA   Hassan S., Purdie K.J., Wang J., Harwood C.A., Proby C.M.,
RA   Pourreyron C., Mladkova N., Nagano A., Dhayade S., Athineos D.,
RA   Caley M., Mannella V., Blyth K., Inman G.J., Leigh I.M.;
RT   "A Unique panel of patient-derived cutaneous squamous cell carcinoma
RT   cell lines provides a preclinical pathway for therapeutic testing.";
RL   Int. J. Mol. Sci. 20:3428.1-3428.26(2019).
//